Marksans Pharma Ltd (MARKSANS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 604869, "name": "Marksans Pharma", "stock_name": "Marksans Pharma", "full_name": "Marksans Pharma Ltd", "name_url": "stocks-analysis/marksans-pharma", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "197.76", "chg": -5.26, "chgp": "-2.59%", "dir": -1, "prev_price": "203.02", "mcapval": "9,138.00 Cr", "mcap": "Small Cap", "scripcode": 524404, "symbol": "MARKSANS", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE750C01026", "curr_date": "May 08", "curr_time": "", "bse_nse_vol": "16.6 lacs", "exc_status": "Active", "traded_date": "May 08, 2026", "traded_date_str": "2026 05 08", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/marksans-pharma-604869-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Marksans Pharma Ltd Surges 8.77% to Day's High of Rs 203.45 — Outperforms Sector by 6.99 Percentage Points", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-hits-intraday-high-with-strong-877-surge-3977816", "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MarksansPharmaL_priceRelatedfactors_3977816.png", "date": "2026-05-06 11:16:02", "description": "The Sensex edged up a modest 0.17% on 6 May 2026, while Marksans Pharma Ltd surged 8.77%, touching an intraday high of Rs 203.45. This 6.99-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector signals a distinctly stock-specific rally rather than a broad market lift." }, { "title": "Marksans Pharma Declines 2.94%: 3 Key Factors Driving the Weekly Slide", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-declines-294-3-key-factors-driving-the-weekly-slide-3971738", "imagepath": "", "date": "2026-05-02 16:06:25", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>27 Apr:</strong> Stock opens strong at Rs.191.95 (+0.89%) amid positive market sentiment</p>\n <p><strong>28 Apr:</strong> Technical momentum shifts; stock drops 3.86% to Rs.184.55 following downgrade to Sell</p>\n <p><strong>29 Apr:</strong> Slight recovery with Rs.187.55 close (+1.63%) despite cautious outlook</p>\n <p><strong>30 Apr:</strong> Valuation concerns rise; stock closes at Rs.184.65 (-1.55%) amid expensive rating</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.190.25</div></div>\n ..." }, { "title": "Marksans Pharma Ltd Valuation Shifts Signal Price Attractiveness Challenges", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-valuation-shifts-signal-price-attractiveness-challenges-3969345", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MarksansPharmaL_valuationdot_3969345.png", "date": "2026-04-30 08:00:28", "description": "Marksans Pharma Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory, reflecting a change in price attractiveness amid evolving market dynamics. This article analyses the recent valuation changes, compares them with peer averages and historical benchmarks, and assesses the implications for investors." }, { "title": "Marksans Pharma Downgraded to Sell Amid Technical Weakness and Flat Financials", "link": "https://www.marketsmojo.com/news/stock-recommendation/marksans-pharma-downgraded-to-sell-amid-technical-weakness-and-flat-financials-3967632", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MarksansPharmaL_mojoScore_3967632.png", "date": "2026-04-29 08:15:44", "description": "Marksans Pharma Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 28 Apr 2026. This revision reflects a combination of deteriorating technical indicators, a shift in valuation perception, and subdued financial trends, despite the company’s strong institutional backing and net-debt-free status." }, { "title": "Marksans Pharma Ltd Technical Momentum Shifts Amid Mixed Indicator Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3965560", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MarksansPharmaL_technicaldot_3965560.png", "date": "2026-04-28 08:03:02", "description": "Marksans Pharma Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite this, certain weekly indicators suggest pockets of bullishness, reflecting a complex interplay of market forces for this small-cap pharmaceutical player." }, { "title": "Marksans Pharma Gains 5.96%: 4 Key Factors Driving the Weekly Rally", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-gains-596-4-key-factors-driving-the-weekly-rally-3962691", "imagepath": "", "date": "2026-04-25 16:08:52", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>20 Apr:</strong> Stock opens at Rs.176.85, down 1.50% amid flat Sensex</p>\n <p><strong>22 Apr:</strong> Price rebounds with 1.53% gain to Rs.179.60</p>\n <p><strong>23 Apr:</strong> Intraday high of Rs.193.55 with 7.04% surge; strong volume spike</p>\n <p><strong>24 Apr:</strong> MarketsMOJO upgrades rating to Hold; valuation shifts to expensive</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.179.55</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div cl..." }, { "title": "Marksans Pharma Ltd Upgraded to Hold by MarketsMOJO on Improving Technicals and Stable Financials", "link": "https://www.marketsmojo.com/news/stock-recommendation/marksans-pharma-ltd-upgraded-to-hold-by-marketsmojo-on-improving-technicals-and-stable-financials-3960229", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MarksansPharmaL_mojoScore_3960229.png", "date": "2026-04-24 08:10:39", "description": "Marksans Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and valuation metrics. Despite flat recent financial performance, improvements in technical indicators and a reassessment of valuation have prompted this change, signalling cautious optimism for investors in this small-cap pharmaceutical player." }, { "title": "Marksans Pharma Ltd Shares Gain Momentum Amid Mixed Technical Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-shares-gain-momentum-amid-mixed-technical-signals-3960080", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MarksansPharmaL_technicaldot_3960080.png", "date": "2026-04-24 08:01:36", "description": "Marksans Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. The stock’s recent 7.49% surge to ₹193.05, following a previous close of ₹179.60, underscores renewed investor interest amid mixed monthly and weekly technical readings." }, { "title": "Marksans Pharma Ltd Valuation Shifts Signal Changing Market Sentiment", "link": "https://www.marketsmojo.com/news/stocks-in-action/marksans-pharma-ltd-valuation-shifts-signal-changing-market-sentiment-3960012", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MarksansPharmaL_valuationdot_3960012.png", "date": "2026-04-24 08:00:25", "description": "Marksans Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting evolving market perceptions and price attractiveness. This article analyses the recent changes in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical trends and peer benchmarks to provide a comprehensive view of the stock’s current standing." } ], "total": 352, "sid": "604869", "stock_news_url": "https://www.marketsmojo.com/news/marksans-pharma-604869" }, "announcements": [ { "details": "Marksans Pharma Limited has submitted to the Exchange a copy of disclosure of Related Party transactions under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended September 30, 2019.", "source": "NSE", "caption": "Marksans Pharma Limited - Other General Purpose", "datetime": "26-Nov-2019" }, { "details": "Marksans Pharma Limited has informed the Exchange regarding Investor Presentation for second quarter September 30, 2019..", "source": "NSE", "caption": "Marksans Pharma Limited - Investor Presentation", "datetime": "13-Nov-2019" }, { "details": "Marksans Pharma Limited has informed the Exchange about Redemption of Unlisted 7% Redeemable Cumulative Preference Shares", "source": "NSE", "caption": "Marksans Pharma Limited - Redemption", "datetime": "31-Oct-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Marksans Pharma Ltd has declared <strong>80%</strong> dividend, ex-date: 01 Aug 25", "dt": "2025-08-01", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Marksans Pharma Ltd has announced <strong>1:10</strong> stock split, ex-date: 11 Mar 08", "dt": "2008-03-11", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

20 Apr: Stock opens at Rs.176.85, down 1.50% amid flat Sensex

22 Apr: Price rebounds with 1.53% gain to Rs.179.60

23 Apr: Intraday high of Rs.193.55 with 7.04% surge; strong volume spike

24 Apr: MarketsMOJO upgrades rating to Hold; valuation shifts to expensive

Week Open

Rs.179.55

Week Close

Read full news article

Marksans Pharma Ltd Upgraded to Hold by MarketsMOJO on Improving Technicals and Stable Financials

2026-04-24 08:10:39

Marksans Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and valuation metrics. Despite flat recent financial performance, improvements in technical indicators and a reassessment of valuation have prompted this change, signalling cautious optimism for investors in this small-cap pharmaceutical player.

Read full news article

Marksans Pharma Ltd Shares Gain Momentum Amid Mixed Technical Signals

2026-04-24 08:01:36

Marksans Pharma Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. The stock’s recent 7.49% surge to ₹193.05, following a previous close of ₹179.60, underscores renewed investor interest amid mixed monthly and weekly technical readings.

Read full news article

Marksans Pharma Ltd Valuation Shifts Signal Changing Market Sentiment

2026-04-24 08:00:25

Marksans Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, reflecting evolving market perceptions and price attractiveness. This article analyses the recent changes in key valuation metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, comparing them with historical trends and peer benchmarks to provide a comprehensive view of the stock’s current standing.

Read full news article